Review Article
Hsp90 Inhibitors for the Treatment of Chronic Myeloid Leukemia
Figure 2
Currently available BCR-ABL specific TKIs for CML treatment. (a) First-generation TKI. ((b), (c), and (d)) Second-generation TKIs. (e) Third-generation TKI.
(a) Imatinib |
(b) Dasatinib |
(c) Nilotinib |
(d) Bosutinib |
(e) Ponatinib |